General Psychiatry

**Electroconvulsive therapy, catatonia, deep vein thrombosis and anticoagulant treatment: a case report**

Ana Pérez-Balaguer, Irene Sánchez-Rivero

**ABSTRACT**

Electroconvulsive therapy (ECT) is considered an effective treatment for pharmacotherapy-resistant severe mental disorders. Catatonia is a complex syndrome characterised by important psychomotor disturbances. Deep vein thrombosis (DVT) and pulmonary embolism (PE) are frequent side effects of prolonged immobility in catatonic patients. Therefore, it is important to resolve the catatonia as soon as possible. ECT is the most effective therapy available and is generally considered a safe procedure. Nevertheless, its use in patients with DVT or PE and anticoagulant treatment remains controversial.

We describe a case of a woman in her 40s with a previous diagnosis of bipolar disorder and dysfunctional personality traits. She was hospitalised with persecutory and reference delusions, high emotional lability, anxiety, somatisation and regressive conduct. She later developed catatonic symptoms. No progress was achieved after a month of hospitalisation, despite several pharmacological treatments. She suffered multiple complications of prolonged immobility, such as an extensive DVT of the left common femoral, the external iliac and the common iliac veins. ECT was conducted under treatment with bemiparin. After the third administration, she showed improvement. No major bleeding or PE was developed. The safety of ECT while receiving anticoagulant therapy has been documented, though dosage and type of anticoagulant must be considered. Location of DVT (proximal or distal) may be an important topic to take into account. This report provides further evidence on the efficacy and safety of undergoing ECT in the context of concomitant serious medical conditions, such as DVT and anticoagulant therapy administration.

**INTRODUCTION**

Electroconvulsive therapy (ECT) might improve pharmacotherapy-resistant, severe mental disorders such as depression, mania, schizophrenia or catatonia, regardless of the underlying diagnosis. Catatonia is a complex syndrome characterised by a considerable psychomotor disturbance, which may range from marked unresponsiveness to marked agitation. Clinical presentation may include stupor, catalepsy, waxy flexibility, mutism, negativism, posturing, stereotypies, echolalia or echopraxia. It can occur in the context of various mental disorders and other medical conditions.

Catatonic patients often experience prolonged periods of immobility, increasing the risk of blood stasis and, as a result, deep vein thrombosis (DVT) or a pulmonary embolism (PE). Other complications, such as decubitus ulcer, rhabdomyolysis, infections, urinary retention and flexion contractures, might also occur. Therefore, it is important to resolve the catatonia as soon as possible.

Although ECT is generally considered a safe and effective procedure for catatonic symptoms, its use in patients with DVT and anticoagulant treatment is still controversial. To provide further evidence on this topic, we report the case of a patient who presented with catatonic symptoms and extensive DVT. ECT was conducted under anticoagulation treatment, ultimately resulting in the patient showing improvement and without developing any complications.

**CASE REPORT**

The patient was a woman in her 40s, with a previous diagnosis of bipolar disorder and dysfunctional personality traits. She also suffered from fibromyalgia, chronic fatigue syndrome and generalised spondylarthrosis. She had two previous admissions and an outpatient follow-up since 2001 and a history of multiple psychopharmacological treatments. She was hospitalised with persecutory and reference delusions, emotional lability, anxiety, somatisations and regressive conduct. She referred to autolytic ideas, owing to her illnesses, ailments and physical limitations. At admission, she was taking quetiapine 500 mg, topiramate 50 mg, lorazepam 30 mg, clorazepate 100 mg and venlafaxine 300 mg daily; morphine and tramadol on demand. The admission blood test showed no coagulation abnormalities: prothrombin time (PT) 13.40 (reference value (RV): 11.0–15.3) s, prothrombin activity (PA) 100.00% (RV: 100.00–140.00).
The patient was discharged after 3 months without psychotic or mood symptoms. She maintained certain anxiety and chronic somatisations. She was diagnosed with histrionic personality disorder, unspecified dissociative disorder, and benzodiazepine and opioid dependence according to the International Statistical Classification of Diseases and Related Health Problems, 10th Edition. Treatment at discharge was enalapril 225 mg, mirtazapine 30 mg, trazodone 100 mg, pregabalin 50 mg, olanzapine 7.5 mg and bemiparin 7500 UI daily. The coagulation blood test at discharge showed PT 12.90 (RV: 11.0–15.3) s, PA 100.00% (RV: 70.0%–120.0%), INR 1.00 (RV: 0.8–1.2), APTT 31.80 (RV: 29.2–39.0) s.

After hospitalisation, the patient was followed up at the Mental Health Centre and the Community Social Support Team for 1 year, showing improvement. She has not presented any further admissions. At the end of 2020, the patient was lost to follow-up. At this time, she maintained somatic complaints and anxiety related to agoraphobia. She did not present any other affective or psychotic symptoms.

**DISCUSSION**

The use of ECT in patients with venous thromboembolism (VTE) and anticoagulant treatment is still a debated topic. Although cases of PE in patients with previous DVT who have undergone ECT sessions have been reported, the risk remains unclear. Some authors suggest that muscle contractions during a seizure can dislodge a clot from residual DVT, despite the use of succinylcholine, therefore increasing the risk of PE. Nonetheless, several reports show that ECT can be performed safely without major complications in patients with prior DVT.

It has been suggested that there may be an association between the location of the residual DVT and the onset of PE. In a recent case series, various patients with distal DVT and anticoagulant treatment received ECT without complications. Meanwhile, a patient suffering proximal DVT developed PE one day after the second ECT session. On the other hand, several cases of proximal DVT have safely undergone ECT treatment as happened with our patient. Given the inconsistency, it has been recommended that anticoagulation should be continued until the resolution of proximal DVT, before going through the ECT sessions safely. ECT is also safe in patients with PE, after proper stabilisation of the medical conditions and initiation of anticoagulant treatment.

Concerns about intracerebral haemorrhage have been raised regarding the use of ECT in patients undergoing anticoagulant therapy since ECT increases momentarily systemic and intracerebral blood pressure. In this context, the safety of ECT during the administration of anticoagulant therapy has been reported. However, two matters should be taken into consideration: the dosage and the type of anticoagulant. While
an overdose may induce an intracerebral haemorrhage during ECT, suboptimal anticoagulation can contribute to the recurrence of thrombosis.12 Regarding the type of anticoagulant, some data demonstrate the safety of treatment with heparin,2 4 12 14 as well as with warfarin,11 while undergoing ECT. A case series of 35 patients, who had undergone a total of 300 ECT sessions while receiving long-term warfarin treatment, showed no intracerebral haemorrhage despite increases in blood pressure and pulse rate.11 However, some authors recommended the use of heparin instead of warfarin, owing to its shorter half-life, which allows its transitory discontinuation before each ECT session and its resumption after electroconvulsive therapy.12 14 For instance, Suzuki et al interrupted a patient’s heparin infusion 2 hours before each ECT session to prevent brain haemorrhage, with good results.12 Regarding our patient, the administration time of bemiparin was strictly controlled before and after ECT sessions, to minimize the bleeding risk. In any case, when warfarin or heparin is used, adequate values of INR or APTT, respectively, should be achieved to reduce the risk of bleeding.12 Recently, dabigatran, rivaroxaban, apixaban and edoxaban have emerged as direct oral anticoagulants, constituting the optimal first-line treatment for VTE in uncomplicated patients.15 They are associated with a slightly lower risk of haemorrhage compared with warfarin; hence they are a convenient alternative of treatment.5,15 Several reports have demonstrated the safety of treatment with these types of anticoagulants.2 5 10 13 16 17 For instance, a recent case series described eight patients with severe psychiatric conditions who were taking either rivaroxaban, apixaban or edoxaban for DVT. They were successfully treated with ECT, without major bleeding complications.5 It is worth noting that no evidence to date reports the optimal duration of anticoagulant treatment before ECT, which should be a focus of attention in further studies.

In conclusion, it is important to address catatonic symptoms as soon as possible to avoid medical complications. This report provides further evidence about the efficacy and safety of ECT in a patient with proximal DVT and anticoagulant treatment with bemiparin. However, the available evidence on this matter is still scarce and mostly consists of case reports or small case series. Controlled studies are necessary to support the use of ECT in patients with VTE and anticoagulation treatment.

Contributors Both authors made a significant contribution to this study and have read and approved its final version. Both authors were involved in the follow-up and treatment of the patient during her admission to the inpatient unit. AP-B obtained informed consent from the patient for the publication of the article. She also carried out the bibliographic search related to the topic and wrote the main part of the article. IS-R completed the bibliographic search and carried out the revision and correction of the text, contributing to the drafting of the article.

Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

Competing interests None declared.

Patient consent for publication Obtained.

Ethics approval This study does not involve human participants.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been peer-reviewed. Any opinions or recommendations discussed are solely those of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and responsibility arising from any reliance placed on the content. Where the content includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iD Ana Pérez-Balaguer http://orcid.org/0000-0002-2894-4156

REFERENCES
Ana Pérez-Balaguer graduated in medicine from the Universidad Autónoma de Madrid in 2017 and she is currently studying for a master’s degree in integrative psychotherapy at the University of Alcalá in Spain. At present, she is developing her professional and training activity as a fourth-year Internal Resident Doctor at the Psychiatric Department of the Hospital Universitario Puerta de Hierro de Majadahonda, Madrid, Spain. In addition, she enrolled in the PhD programme at the Universidad Autónoma de Madrid in June 2021. Her main research interest includes the role of impulsivity in a suicidal population.